CLINICAL_TRIALS
trial_result
· 2024-03-05
Clinical Trial Update: CVL237 Tablets for APDS/PASLI [Phase 2, Phase 3]
Summary
Phase 2/Phase 3 clinical trial update for CVL237 tablets in PI3K and P110delta hyperactivation syndrome (APDS/PASLI). Status not specified.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Convalife (Shanghai) Co., Ltd. | Conditions: PI3K and P110delta Hyperactivation Syndrome | Phase 2, Phase 3 | Status: UNKNOWN